At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 145 enrolled
Drug / intervention
Pandemrix (GSK investigational influenza GSK2340272A vaccine) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A
In Brief
A Phase 3 clinical trial evaluating Pandemrix (GSK investigational influenza GSK2340272A vaccine), Fluarix™, and 1 other intervention for Influenza. Completed, enrolled 145 participants across 6 sites.
Detailed Summary
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartSep 2009
Primary CompletionNov 2009
Study CompletionOct 2010
TodayJul 2026
First PostedSep 3, 2009
Enrollment StartSep 8, 2009
Primary CompletionNov 16, 2009
Study CompletionOct 8, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.8 years ago
Interventions
Pandemrix (GSK investigational influenza GSK2340272A vaccine)biological
2 doses intramuscular injections
Fluarix™biological
1 dose intramuscular injection
Placebobiological
1 dose intramuscular injection